{
    "root": "1468f2ff-4355-402a-8c46-0b9272ae633e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Pioglitazone Hydrochloride and Metformin Hydrochloride"
    },
    "value": "20250227",
    "ingredients": [
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE CALCIUM",
            "code": "UTY7PDF93L"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. \n                  \n                  \n                     Limitations of Use\n                  \n                  Pioglitazone and metformin hydrochloride tablets are not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis.",
    "contraindications": "Obtain liver tests before initiation. If abnormal, use caution when treating with pioglitazone and metformin hydrochloride, investigate the probable cause, treat (if possible), and follow appropriately. ( 2.1 ) Take orally with meals to reduce gastrointestinal adverse reactions with metformin (2.10) Individualize the starting dose based on the patient’s current regimen and titrate the dosage gradually, as needed after assessing therapeutic response and tolerability. The maximum recommended total daily dosage is pioglitazone 45 mg and metformin 2,550 mg. ( 2.2 ) Recommended starting dosage in patients with NYHA Class I or Class II congestive heart failure is 15 mg of pioglitazone and 500 mg of metformin hydrochloride or 15 mg of pioglitazone and 850 mg of metformin hydrochloride orally once daily. ( 2.4 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). ( 2.2 ) Contraindicated in patients with eGFR below 30 mL/min Initiation is not recommended in patients with eGFR between 30 to 45 mL/min Assess risk/benefit of continuing pioglitazone and metformin hydrochloride if eGFR falls below 45 mL/min Discontinue if eGFR falls below 30 mL/min Monitor patients for adverse events related to fluid retention after initiation and dose increases. ( 2.4 ) Pioglitazone and metformin hydrochloride may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. ( 2.6 )",
    "warningsAndPrecautions": "Pioglitazone and Metformin Hydrochloride Tablets USP, 15 mg/500 mg are white to off-white, oblong, biconvex film-coated tablets, debossed with ‘H’ on one side and ‘92’ on other side.\n                           Bottles of 60                               NDC 65862-525-60       Bottles of 180                             NDC 65862-525-18 \n                     \n                     Pioglitazone and Metformin Hydrochloride Tablets USP, 15 mg/850 mg are white to off-white, oblong, biconvex film-coated tablets, debossed with ‘H’ on one side and ‘93’ on other side.\n                           Bottles of 60                               NDC 65862-526-60       Bottles of 180                             NDC 65862-526-18 \n                     \n                     Storage: \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Keep container tightly closed, and protect from moisture and humidity.",
    "adverseReactions": "Pioglitazone and metformin hydrochloride are contraindicated in patients with:\n                  \n                     Established NYHA Class III or IV heart failure at the time of pioglitazone and metformin hydrochloride initiation [see Boxed Warning].\n                     Severe renal impairment (eGFR below 30 mL/min) [see Warnings and Precautions (5.2)].\n                     A history of serious hypersensitivity to pioglitazone, metformin hydrochloride, or any of the excipients in pioglitazone and metformin hydrochloride tablets. \n                     Acute or chronic metabolic acidosis, including diabetic ketoacidosis [see Warnings and Precautions (5.2)]."
}